NKTR

NKTR is not a 'company' to value on its income statement — it's a clinical-stage immunology pipeline wrapped around one asset, rezpegaldesleukin. The reported $55.2M FY2025 revenue (down 43.9%) is residual collaboration/royalty income, not product sales, so the 34x P/S is economically meaningless; the stock is a binary bet on the pipeline. The bull case got materially stronger on June 24, 2025, when the Phase 2b REZOLVE-AD trial (393 patients) hit its primary EASI endpoint across all three dose arms (p<0.001) plus key secondary endpoints, with FDA Fast Track in both atopic dermatitis and alopecia areata. A de-risked, partner-able Treg-agonist in the multi-billion-dollar AD market is the entire reason a non-commercial company carries a $1.88B cap.

The problem is the balance sheet against the spending plan. Operating cash flow was -$209M in FY2025 and management explicitly guides that total R&D will 'increase significantly' in 2026 as it initiates the Phase 3 AD program — the single most expensive phase of drug development. Against that, cash & equivalents are just $15.1M; even counting the full $266M of current assets (the bulk in short-term investments), that is roughly one year of runway into an accelerating burn. With $0 buybacks and shares already restructured (count down 84.6% YoY, consistent with a reverse split, not value return), a dilutive raise or a partnership on someone else's terms looks close to unavoidable. ROE of -182.6% and a -$3.76B accumulated deficit underline that this has never thrown off cash.